Get started
Author

Nadia Anceriz

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
2019 · Laurent Gauthier, Ariane Morel, et al. · Cell · 454
PDF
Blockade of Antimicrobial Proteins S100A8 and S100A9 Inhibits Phagocyte Migration to the Alveoli in Streptococcal Pneumonia
2008 · Marie-Astrid Raquil, Nadia Anceriz, et al. · The Journal of Immunology · 142
PDF
An Inflammation Loop Orchestrated by S100A9 and Calprotectin Is Critical for Development of Arthritis
2012 · Annabelle Cesaro, Nadia Anceriz, et al. · PLoS ONE · 120
PDF
S100A9 mediates neutrophil adhesion to fibronectin through activation of β2 integrins
2007 · Nadia Anceriz, Karen Vandal, et al. · Biochemical and Biophysical Research Communications · 77
Anti-CD79 Antibody Induces B Cell Anergy That Protects against Autoimmunity
2014 · Ian R Hardy, Nadia Anceriz, et al. · The Journal of Immunology · 44
PDF
Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies
2011 · Giovanni Magistrelli, Pauline Malinge, et al. · Journal of Immunological Methods · 16
NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2025 · Sara Majocchi, Pauline Lloveras, et al. · Cancer Immunology Research · 12
PDF
Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control
2021 · Mathieu Bléry, Manel Mrabet-Kraiem, et al. · Open Research Europe · 8
Abstract 1491: IPH4301, an antibody targeting MICA and MICB exhibits potent cytotoxic activity and immunomodulatory properties for the treatment of cancer
2016 · Ariane Morel, Nicolas Viaud, et al. · Cancer Research · 4
A third-generation, high-affinity biparatopic anti-tau antibody inhibits intracellular tau aggregation seeded by Alzheimer’s brain extracts
2026 · Eric Hatterer, Lucile Broyer, et al. · Alzheimer s Research & Therapy
Figure S13 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S01 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S06 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S03 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S14 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S01 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S05 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S06 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S17 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S12 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S16 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S10 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S04 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Table S04 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Figure S07 from NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
2026 · Sara Majocchi, Pauline Lloveras, et al.
Works count: 62
Citation count: 877
H-index: 8
I10-index: 7
Year
Topic
Type